Clinical trials: High-Risk Oral Precancerous Disease
Oral Leukoplakia
Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia
This is a Phase IIa oral cavity leukoplakia study of pioglitazone 15mg and metformin 500mg BID for 12 weeks. The primary objective is to determine the clinical and histologic changes of leukoplakia from baseline following a 12…
- Trial name
- NCT05727761
- Testing
- pioglitazone-metformin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of Minnesota
Leukoplakic Lesions
Comparison Between Two Different High Power Ablative Lasers in the Treatment of Oral Leukoplakia
Oral leukoplakia is a precancerous lesion with relatively high malignant transformation potential. They are often treated by wide surgical excisions or conservative retinoids therapy.
- Trial name
- NCT03233165
- Testing
- Er:YAG laser, Er,Cr:YSGG laser
- Volunteers
- 54 people
- Sponsor
- University of Zagreb
Leukemia, Leukemia, Myeloid
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome…
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia
- Trial name
- NCT06501196
- Testing
- BH-30236, Venetoclax
- Where
- 13 sites in United States
- Volunteers
- 170 people
- Sponsor
- BlossomHill Therapeutics
Cancer Risk, Cancer Predisposition Syndrome
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member…
- Conditions
- Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors
- Trial name
- NCT05463796
- Testing
- Samples
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Human Papilloma Virus
Zinc Sulfate for Human Papillomavirus (HPV)
The Human Papillomavirus (HPV) is well established as the primary causative agent in both warts and cervical cancer. Although cervical high risk HPV (hrHPV) infections have a high rate of spontaneous resolution this takes time…
- Trial name
- NCT03404310
- Testing
- Zinc Sulfate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Corewell Health West
Oral Cancer, Oral Cavity Cancer
Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions
The primary goal of this study is to see if photodynamic therapy (PDT) is effective for treatment of lesions in the oral cavity which have high risk of becoming oral cancer.
- Conditions
- Oral Cancer, Oral Cavity Cancer, Oral Leukoplakia, Oral Lichen Planus
- Trial name
- NCT06876038
- Testing
- 5-Amino Levulinic Acid
- Where
- 2 sites in India
- Volunteers
- 65 people
- Sponsor
- University of Massachusetts, Boston
Oral Cancer, Oral Premalignant Lesion
Innovative Approach to Triage Oral Precancer
Oral cancer is a major health problem worldwide, accounting for 274,000 new cases and 145,000 deaths annually. On average, half of the patients die within 5 years of an oral cancer diagnosis.
- Trial name
- iTOP (NCT03202810)
- Where
- Canada
- Volunteers
- 360 people
- Sponsor
- British Columbia Cancer Agency
Oral Cavity Cancer, Premalignant Lesion
Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL
The aim of this study is to involve high-risk patients with a history of malignant transformation in oral potentially malignant disorders. We will use a combination of Cardunil and all-trans retinoic acid for intervention.
- Trial name
- NCT06728631
- Testing
- Candonilimab and ATRA, other treatment or observation
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Barrett Esophagus
Pilot Study of Oral 852A for Elimination of High-Grade Dysplasia in Barrett's Esophagus
Barrett's esophagus with high-grade dysplasia is a premalignant condition caused by chronic reflux of gastric contents into the esophagus. High-grade dysplasia is the same as carcinoma-in-situ.
- Trial name
- NCT00386594
- Testing
- 852A
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Rogers, B.H. Gerald, M.D.
Breast Cancer, Cervical Cancer
EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma
RATIONALE: EF5 may detect the presence of oxygen in tumor cells and help plan effective cancer treatment. PURPOSE: Phase I trial to study the effectiveness of EF5 in detecting the presence of oxygen in tumor cells of patients who…
- Conditions
- Breast Cancer, Cervical Cancer, Head and Neck Cancer, Prostate Cancer
- Trial name
- NCT00004261
- Testing
- EF5, flow cytometry, fluorescent antibody technique
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia (CIN)
Dual-Modality Immunotherapy for HPV Clearance (DUAL-HPV)
Persistent high-risk human papillomavirus infection is an important precursor of cervical cancer and related cervical lesions. This single-center, randomized, assessor-blinded, parallel-group controlled trial evaluates whether…
- Conditions
- Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia (CIN), Low-Grade Squamous Intraepithelial Lesions
- Trial name
- DUAL-HPV (NCT07735039)
- Testing
- Oral Immunomodulator, Vaginal Ovule, Standard Supportive Care
- Where
- Turkey (Türkiye)
- Volunteers
- 76 people
- Sponsor
- Dr. Lutfi Kirdar Kartal Training and Research Hospital
Head and Neck Cancer, Precancerous Condition
Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract
RATIONALE: Monoclonal antibodies, such as cetuximab, can block abnormal cell growth in different ways. Some block the ability of abnormal cells to grow and spread.
- Trial name
- NCT00524017
- Testing
- cetuximab
- Where
- 10 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mouth Diseases
Evaluation of Oral Potentially Malignant Disorders (OPMDs) with STRATICYTE™
The purpose of this study is to validate the ability of the STRATICYTE™ predictive model to predict the transformation of oral potentially malignant disorders (OPMDs) to oral squamous cell carcinoma (OSCC) in a retrospective…
- Trial name
- NCT05853783
- Testing
- STRATICYTE™ Test
- Where
- 5 sites in United States
- Volunteers
- 180 people
- Sponsor
- Proteocyte Diagnostics Inc.
Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections
A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)
This is a non-randomized, open label study to assess the reduction of Human Papillomavirus (HPV) infectivity and transmission in women positive for HPV16 and/or 18 in a cervical, oral and anal sample and vaccinated with…
- Conditions
- Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections, High-risk HPV, HPV-16/ 18
- Trial name
- RIFT-HPV (NCT05334706)
- Testing
- Nonavalent HPV vaccine (9vHPV/Gardasil-9™).
- Where
- Spain
- Volunteers
- 69 people
- Sponsor
- Miquel Angel Pavon Ribas
High-Risk Oral Precancerous Disease
Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease
The goal of this study is to understand the safety, tolerability, and potential efficacy of an injected immune therapy called RP2 to treat oral precancer conditions and prevent progression to an oral cancer.
- Trial name
- INTERCEPT (NCT06623110)
- Testing
- RP2 Injection
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Glenn J. Hanna
Oral Neoplasm
Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment
The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral…
- Trial name
- NCT04622462
- Testing
- Standard of Care Histopathology, STRATICYTE Assessment
- Where
- 3 sites in Canada
- Volunteers
- 500 people
- Sponsor
- Proteocyte Diagnostics Inc.
Oral Cavity Cancer, Mouth Neoplasm
Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization
This is a non-randomized, phase II, open-label study. The goal of this clinical research study is to investigate how well sintilimab works in preventing high-risk oral premalignant lesions cancerization.
- Conditions
- Oral Cavity Cancer, Mouth Neoplasm, Precancerous Conditions
- Trial name
- STOP (NCT04065737)
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Lung Cancer, Precancerous Condition
Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer
RATIONALE: Calcitriol may prevent lung cancer in patients with metaplasia or dysplasia of the lungs. PURPOSE: This clinical trial is studying the side effects and best dose of calcitriol in preventing lung cancer in current…
- Conditions
- Lung Cancer, Precancerous Condition, Tobacco Use Disorder
- Trial name
- NCT00690924
- Testing
- calcitriol, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute